News
After FDA no, MSD/Daiichi post new data with lung cancer ADC
MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective …
19694 items found
News
Tobacco firm PMI divests Vectura at a loss after backlash
Philip Morris International (PMI) is selling inhaled drug specialist …
R&D
Partner Content
7th RNA-Targeted Drug Discovery & Development Summit
Optimizing Lead Discovery, Structural Analysis & Preclinical Modeling …
R&D
Partner Content
9th CDD For Biologics Summit 2024
Integrate Computational Biology, Generative AI & Machine Learning to …
R&D
Partner Content
Targeted Radiopharmaceuticals Summit EU 2024
As radiopharmaceutical innovation flourishes and collaboration …
Oncology
Market Access
The critical importance of payer-provider collaboration goes beyond prior authorisation
The critical need to improve prior authorisation processes might have …
News
FDA clears sleep apnoea feature for new Apple Watch
Apple has the FDA authorisation it needs to bring its software for …
Sales & Marketing
Sponsored
Mitigating diagnostic errors in clinical trial participants: The role of drug safety/pharmacovigilance
A diagnosis identifies a patient’s health problem and is a key to …
News
Trial sets up filings for Boehringer IPF drug nerandomilast
With new phase 3 data in hand, Boehringer Ingelheim is preparing to …
News
ESMO: Pfizer drug helps cancer patients gain weight
Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight …
News
ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer
Johnson & Johnson is planning a phase 3 programme for Rybrevant in …
News
Sage cuts a third of its workforce after R&D setbacks
Sage Therapeutics has launched another round of layoffs as it deals with the fallout of abandoning a key pipeline drug for Alzheimer's and Parkinson's disease.
Digital
Sponsored
Decoding physician prescribing behaviour: A data-driven jour...
Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.
Sales & Marketing
Deep Dive: Commercialisation 2024
In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
R&D
LSX 2024 - Dr Tadaaki Taniguchi
At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at Astellas Pharmaceuticals to talk a bit about the company and some r
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
BIO-Europe's 30th Anniversary Landmark Event in Stockholm
BIO-Europe™ celebrates 30 years of facilitating partnerships this Fall. In 1994, BIO-Europe launched with the mission to drive biotech innovation and
R&D
Partner Content
8th Dermatology Drug Development Summit
Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
